All In Biotech

Drug Trial Radar · NCT07596199

A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Japanese Healthy Pregnant Women

A Phase 3, Non-Randomized, Single-Arm, Open-Label Study to Assess the Immunogenicity, Safety and Reactogenicity of a Single Dose of Combined Reduced-Antigen-Content Diphtheria, Tetanus and Acellular Pertussis (dTpa) Vaccine in Japanese Healthy Pregnant Women

Last checked: Nov 20, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

102

Actual

Start

Jun 29, 2026

Primary completion

Nov 23, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
May 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this Phase 3, non-randomized, single-arm, open-label study is to evaluate the immune response, reactogenicity and safety of GSKs dTpa vaccine in Japanese pregnant women between 27 weeks and less than 37 weeks of pregnancy. Both the pregnant women and their neonates born during the study will be evaluated for specific analyses.

Conditions

  • Diphtheria-Tetanus-acellular Pertussis Vaccines

Interventions

  • dTpaBiological

    1 dose of dTpa vaccine is administered intramuscularly.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of seropositive healthy pregnant women for anti-pertussis toxin (PT), anti-filamentous hemagglutinin (FHA) and anti-pertactin (PRN) antibodiesTime frame: At Month 1 post-vaccination
  2. Number of seropositive participants for anti-PT, anti-FHA and anti-PRN antibodies from samples in cord blood sample at birthTime frame: On the Day of birth

Locations

21 sites in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Aichi, Japan

  • GSK Investigational Site

    Chiba, Japan

  • GSK Investigational Site

    Chiba, Japan

  • GSK Investigational Site

    Fukui, Japan

  • GSK Investigational Site

    Fukuoka, Japan

  • GSK Investigational Site

    Fukushima, Japan

  • GSK Investigational Site

    Hokkaido, Japan

  • GSK Investigational Site

    Kanagawa, Japan

  • GSK Investigational Site

    Kanagawa, Japan

  • GSK Investigational Site

    Kyoto, Japan

  • GSK Investigational Site

    Nagano, Japan

  • GSK Investigational Site

    Nara, Japan

  • GSK Investigational Site

    Osaka, Japan

  • GSK Investigational Site

    Osaka, Japan

  • GSK Investigational Site

    Saitama, Japan

  • GSK Investigational Site

    Saitama, Japan

  • GSK Investigational Site

    Shizuoka, Japan

  • GSK Investigational Site

    Shizuoka, Japan

  • GSK Investigational Site

    Tokyo, Japan

  • GSK Investigational Site

    Tokyo, Japan

  • GSK Investigational Site

    Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.